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ABSTRACT  Monoclonal and polyclonal antibodies that bind to myosin-II were tested for their 
ability  to  inhibit  myosin  ATPase activity,  actomyosin  ATPase activity,  and  contraction  of 
cytoplasmic extracts.  Numerous antibodies specifically inhibit the actin activated Mg++-ATPase 
activity  of myosin-II  in  a dose-dependent  fashion,  but  none,blocked  the ATPase activity  of 
myosin alone. Control antibodies that do not bind to myosin-II and several specific antibodies 
that do bind have no effect on the actomyosin-II ATPase activity.  In most cases, the saturation 
of a single  antigenic  site  on the  myosin-II  heavy chain  is sufficient  for maximal  inhibition  of 
function.  Numerous  monoclonal  antibodies  also  block  the  contraction  of gelled  extracts  of 
Acanthamoeba  cytoplasm.  No  polyclonal  antibodies  tested  inhibited  ATPase activity  or  gel 
contraction. As expected, most antibodies that block actin-activated ATPase activity also block 
gel contraction.  Exceptions  were three antibodies M2.2, -15, and -1 7, that appear to uncouple 
the  ATPase activity  from  gel  contraction:  they  block  gel  contraction  without  influencing 
ATPase activity. The mechanisms of inhibition  of myosin function  depends on the location of 
the  antibody-binding  sites. Those  inhibitory  antibodies  that  bind  to  the  myosin-II  heads 
presumably  block actin  binding or essential  conformational  changes  in the  myosin  heads.  A 
subset of the antibodies that bind to the proximal end of the myosin-II tail inhibit actomyosin- 
II ATPase activity and gel contraction.  Although this part of the molecule is presumably some 
distance  from  the ATP and  actin-binding  sites, these antibody  effects  suggest that structural 
domains in this region are directly involved  with or coupled to catalysis and energy transduc- 
tion.  A  subset  of the  antibodies  that  bind  to  the  tip  of the  myosin-II  tail  appear  to  inhibit 
ATPase activity  and  contraction  through their inhibition  of filament  formation.  They provide 
strong evidence for a substantial  enhancement of the ATPase activity of myosin molecules  in 
filamentous form and suggest that the myosin filaments may be required for cell motility. 
There is good evidence that the actin-activated Mg++-ATPase 
of muscle myosin produces the force for muscle contraction 
(reviewed in references 5, 37). By analogy, cytoplasmic myo- 
sins are likely to generate movement in a variety ofnonmuscle 
systems ( 16, 36). Mabuchi and Okuno (19) and Kiehart et al. 
(15) provided the best physiological evidence for the produc- 
tion of force by myosin in a nonmuscle cell. They examined 
the role of myosin in  cytokinesis, nuclear migrations,  and 
chromosome  movements  by  microinjecting  antibodies 
against cytoplasmic myosin into living cells.  In vitro, these 
antibodies inhibited  the  actin-activated  ATPase activity of 
starfish egg myosin. In the injected cells, antibodies specifi- 
cally inhibited  cytokinesis in  an  antibody dose-dependent 
fashion, but the other processes remained unaffected. These 
experiments showed that cytokinesis requires myosin for force 
production, and provided evidence against a role for myosin 
in chromosome movement and nuclear migration. 
We have produced and characterized a  library of mono- 
clonal antibodies to the two  major myosin isozymes from 
Acanthamoeba to use as probes of myosin function (12). We 
demonstrated the specificity of antibody binding and deter- 
mined their relative affinities by evaluating an apparent dis- 
THE JOURNAL OF  CELL BIOLOGY - VOLUME 99  SEPTEMBER 1984  1024-1033 
1 024  © The Rockefeller University Press • 0021-9525/84,109/1024/10  $1.00 sociation constant. Competitive binding studies and antibody 
staining  of  one-dimensional  peptide  maps  of  myosin-II 
showed that the antibodies recognize at least 15 unique anti- 
genic determinants that can be grouped into six families whose 
members bind to sites that are concentrated in six regions of 
the myosin-II molecule. In a  second paper (13),  we directly 
localized the binding sites on myosin-II of some of the anti- 
bodies by electron microscopy of platinum-shadowed and of 
negatively stained specimens. By combining the electron mi- 
croscope  data  with  the  peptide  mapping  and  competitive 
binding studies, we were able to localize the binding sites of 
all but seven of the antibodies. Analysis of antibody effects 
on filament formation demonstrated that two of the 23 anti- 
bodies completely inhibited  the assembly of myosin-II into 
filaments, a  function  likely to be important for the role of 
myosin in cell motility. 
Here we evaluate the effect of monoclonal antibodies on 
the ATPase activities of myosin-II in vitro and use the mon- 
oclonal antibodies to probe myosin function  in  an in  vitro 
model for cell  motility, the contraction of gelled extracts of 
Acanthamoeba cytoplasm. A subset of the antibodies inhibit 
the actomyosin-II ATPase activity and contraction of gelled 
extracts of Acanthamoeba cytoplasm. Three antibodies appear 
to uncouple gel contraction from ATPase activity: they inhibit 
contraction  without  affecting actomyosin  ATPase  activity. 
We document the specificity of inhibition of both functions 
and show that saturation of certain single antigenic sites on 
the myosin-II heavy chain is sufficient to inhibit mechano- 
chemical function. 
The specific mechanism of antibody inhibition of myosin- 
II function depends on the locus of antibody binding to the 
myosin-II molecule. Antibodies that  bind to  the  myosin-|I 
heads and block actomyosin-I! ATPase activity and gel con- 
traction probably do so by interfering with actin binding or 
with conformational changes in the head required for actin- 
activated ATP hydrolysis or cross-bridge cycling. Surprisingly, 
at least two families of antibodies that inhibit actomyosin-II 
ATPase activity and gel contraction  bind to the  myosin-II 
tail. The first group includes some, but not all, of the antibod- 
ies that bind near the junction of the tail with the heads. This 
is striking evidence that  structural  domains on the  myosin 
tail, adjacent to where it joins the heads, contribute to force 
production during cross-bridge cycling. The second group of 
inhibitory antibodies is a subset of the antibodies that bind to 
the tip of the myosin-II tail. A number of strong correlations 
suggest that these antibodies exert their effects through inhi- 
bition of myosin-II filament formation (13,  14). 
Preliminary accounts of this work were presented at meet- 
ings of the  American Society for Cell Biology and the Bio- 
physical Society (9-11). 
MATERIALS  AND  METHODS 
Materials:  Reagent  grade  chemicals  were obtained  from the  sources 
described previously (12). Sources for other materials are given in the text. 
Proteins:  Myosin-II, purified as described previously (12), was dephos- 
phorylated with potato acid phosphatase (Sigma Chemical Co., St. Louis, MO) 
for 5 h at 29"C in 25% sucrose, 150 mM KCI, 10 mM imidazole-Cl, pH 7.0, 1 
mM dithiothreitol,  and 1 mM MgCI2 in the presence of proteolytic inhibitors 
(10 t~g/ml pepstatin,  0.5 ug/ml leupeptin, 0.5 mM phenylmethylsufonyl  fluo- 
ride, all obtained  from Sigma Chemical  Co.) by the  method of Collins and 
Korn (2, 3). To seperate dephosphorylated  myosin-II from the phosphatase, 
the preparation  was chromatographed  on A 15 200-400  mesh (Bio-Rad Labo- 
ratories, Richmond,  CA) equilibrated with 0.6 M KCI, 10 mM imidazole, pH 
7.0, and 5% sucrose. The dephosphorylated  myosin-II had <0.8 tool of phos- 
phate per mole of myosin-II by direct chemical assay (29). It was stored in 20% 
sucrose, 5 mM imidazole-C1, pH 7.0, 3 mM NAN3, I mM dithiothreitol  at 4°C. 
Sucrose preserves the activity of myosin-II during storage for several weeks. 
Monoclonal  antibodies  were produced,  purifed, and characterized  as de- 
scribed previously 02,  13). Each antibody  is named according to its eliciting 
antigen (M2 for myosin-II), followed by a unique integer suffix that designates 
the individual clone that produces it (12). Antibodies were routinely stored at 
4°C in 20% sucrose, 5 mM imidazole-C1, pH 7.0, 3 mM NAN3. 
Antibody  Fab fragments  were made by digesting monoclonal  antibodies 
with papain (32). Monoclonal antibodies (5-13 mg/ml)  were mixed with papain 
(l0 ~g/mg of antibody  [Worthington  Biochemieals, Freehold, NJ]) in l0 mM 
cysteine and 2 mM EDTA, and incubated  12-16 h at 37°C. The preparation 
was chromatographed  on Sephadex G-100 (Pharmacia  Fine Chemicals, Pisea- 
taway, NJ) equilibrated with 0.1  M sodium phosphate,  pH 7.0, 3 mM NaNa, 
to separate the Fab and Fc fragments from the papain. The protein  peak that 
contained  both antibody  fragments was concentrated  by dialysis against solid 
sucrose.  The  preparation  was  adjusted  to  pH  8.0  by  addition  of sodium 
phosphate to a final concentration  of 0.1  M and chromatographed  on Protein 
A Sepharose (Pharmacia  Fine  Chemicals)  to remove  Fc  fragments.  Protein 
which did not bind to the Protein A column was pooled and concentrated  by 
dialysis against solid sucrose. Fab fragments prepared in this fashion ran as a 
single ~25,000-mol-wt  species on PAGE in SDS. 
Protein concentrations  were measured by absorbance using extinction coef- 
ficients of 0.56 cm2/mg at 280 nm for myosin-II, 0.62 cm2/mg at 290 nm for 
Acanthamoeba actin  and  1.4  cm2/mg at  280  nm  for antibodies  and  Fab 
fragments. Methods for SDS PAGE on 14% DATD (N,N'-diallyltartardiamide) 
cross-linked polyacrylamide gels appear elsewhere (29). 
Myosin-II  Concentration  in Cytoplasmic  Extracts of Acan- 
thamoeba:  The myosin-II concentration  in Acanthamoeba extracts was 
measured  with  a  solid-phase  antibody-binding  assay (12)  on  nitrocellulose 
paper. Extract was mixed with SDS sample buffer, boiled, then serially diluted. 
Duplicate  l0  ul  samples  of each  dilution  and  myosin-II  standards  in  SDS 
sample  buffer  were dried  onto  1.5-cm squares  of nitrocellulose  paper.  The 
squares were rinsed several times in STTAB buffer (0.15 M NaCl, l0 mM Tris- 
HCI, pH  7.7,  3  mM  NaNa,  0.1% Triton  X-100,  and  0.1% bovine  serum 
albumin), then incubated with specific antibody (M2.13) against myosin for 2 
h at room temperature.  After washing with STTAB three times, the amount of 
specific antibody bound was measured by reaction with t251-1abeled goat anti- 
mouse antibodies.  The squares  were washed  three  times with  STTAB and 
bound J251 was quantified  in a gamma counter.  The concentration  of myosin- 
II in the extract was determined by comparison  with a dilution series of  purified 
myosin treated in parallel with cell extract samples. 
Myosin  ATPase  Activity:  The  K÷-EDTA  -  and  Ca+÷-activities of 
myosin-II were measured  at 29"C (30). Inorganic  phosphate  was determined 
colorimetrically or by liquid scintillation  using trace gamma-labeled 32P-ATP 
in an excess of cold carrier ATP. Purified antibodies had no ATPase activity of 
their own. 
Actomyosin-II A TPase Activity:  Dephosphorylated  myosin-II was 
used for analysis of antibody effects on actomyosin-II ATPase activity. Under 
the conditions described below, myosin-II Mg÷+-ATPase  activity was activated 
100-400-fold by 0.5 mg/ml actin for each of the five preparations  of dephos- 
phorylated myosin-If used for these experiments. ATP hydrolysis due to actin, 
myosin-II,  and antibody  alone,  was subtracted  from samples  containing  all 
three proteins to determine the ATPase activity due specifically to actomyosin- 
II. Hydrolysis of ATP  due to actomyosin  activity  was linear  with time and 
typically accounted for >93% of the inorganic phosphate measured. 
Antibody effects on the actomyosin-II  ATPase were measured  as follows. 
Equal volumes (typically 20/~l) of myosin-II (0.43 ~M) and antibody in their 
sucrose storage buffers were mixed in small glass culture tubes and preincubated 
at 0*C for 0.5-2  h. Antibody  concentration  was adjusted  depending  on the 
experiment. The reaction was started by adding 360 ~l of a mixture containing 
appropriate  salts, ATP and actin and warming to 29"C. Final solution  condi- 
tions were l0 mM imidazole, 7 mM MgCI2,  0.1 mM CaC12, 0.5 mM ATP, 0.35 
mM dithiothreitol  and 8 to 24 ~tM actin. The reactions were stopped after 25- 
35  rain  by the  addition  of acid. Inorganic  phosphate  was determined  with 
gamma labeled 32p-ATP as described above. 
Extracts of Acanthamoeba  Cytoplasm:  Extracts of Acantham- 
oeba cytoplasm  were prepared  with minor modifications  of the method de- 
scribed previously (26). Washed cells were homogenized in 1.5 vol of sucrose 
extraction buffer (0.34 M sucrose, l0 mM imidazole, pH 7.0, l0 mM ATP,  l 
mM EGTA,  l  mM dithiothreitol)  with 30 strokes of a Dounce homogenizer 
with a tight fitting pestle, l0 mM ATP was used instead of 1 mM ATP because 
the extent of gel contraction  was much more reproducible in 10 mM ATP. 
Gelation and Gel Contraction:  To analyze the effects of antibody 
on gelation and contraction,  we mixed 9 vol of extract with 1 vol of antibody 
in sucrose buffer (20% sucrose, 5 mM imidazole, pH 7.0, 3 mM NAN3) in the 
cold.  Antibody  concentration  was  adjusted  depending  on  the  experiment. 
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capillaries  that were subsequently sealed at one end with Seal Ease (Clay Adams, 
Parsippany, N J). Duplicate capillaries  were prepared for each sample and were 
stored  vertically at  4"C.  After  all the  capillaries were  prepared,  they  were 
transferred to room temPerature (22-25"C). Gelation of extract-antibody mix- 
tures was tested using the falling  ball assay (22). Following  gelation, the samples 
were stored horizontally at room temPerature (22-25"C) and allowed to con- 
tract. With time, the clear, gelled extract became translucent and pulled away 
from the sealed end of the capillary as it syneresed a clear fluid. After 10-16 h 
contraction had  ceased and the  extent of contraction was measured as the 
distance the translucent gel pulled away from the seal in the end of the capillary 
tube.  Remarkably, this measure was highly reproducible. In a  typical exPeri- 
ment controls containing antibody buffer were contracted  11.3  mm (S.D.  = 
0.5 mm, n =  6) out of a total gel length of 50-55 mm. 
RESULTS 
Monoclonal Antibodies Do Not Specifically 
Inhibit the K+-EDTA  - and Ca++-ATPases 
of Myosin-II 
Only  one  of the  22  purified  monoclonal  antibodies  to 
myosin-II inhibits the K÷-EDTA- or Ca+÷-ATPase activities 
of myosin-II (data  not  shown).  In  these  experiments,  we 
preincubated myosin-II with large molar excesses of antibody 
for 30-60 min at 0*C. In all cases except two, antibody was 
present in a  10- to 24-fold molar excess over myosin-II. The 
molar ratios of antibodies M2.9 and M2.13 to myosin-II were 
four and  six,  respectively. M2.21  was not tested.  Antibody 
M2.2 inhibited the Ca÷+-ATPase in a  linear, concentration- 
dependent fashion. However, 50% inhibition required a molar 
ratio  of antibody  to  myosin  of approximately  12:1. This 
suggests that inhibition was not a result of antibody binding 
to myosin, which should have saturated at a  molar ratio of 
about  1:1  or 2:1.  Rather it may have been due to residual 
contaminants from the ascites fluid. Many of the ascites fluids 
contained non-antibody materials that inhibited the myosin 
ATPase or had ATPase activity themselves (data not shown). 
These  contaminants  were  removed  from  all  of the  other 
antibodies  by ammonium  sulfate  fractionation  and  DEAE 
chromatography (12). We conclude that no antibodies specif- 
ically inhibited the ATPase activities of myosin-II alone. 
Monoclonal Antibodies  Inhibit the Actin- 
activated A TPase of Myosin-II 
12 of 19 purified monoclonal antibodies inhibit the actin- 
activated Mg÷÷-ATPase of dephosphorylated myosin-II. We 
screened the antibodies for their ability to inhibit actomyosin- 
II ATPase activity using molar ratios of antibody:myosin-II 
ranging from 23  to  120 (Table I). We preincubated myosin 
and antibody for at least 30 min at 4"C before adding actin 
and  ATP.  Myosin-II samples  preincubated  with  antibody 
buffer alone resulted in (control) actin activated ATPase rates 
of-500 nmol/mg, min when the actin concentration was 0.5 
mg/ml.  In a  molar excess of antibody,  where the  antibody 
binding site on the myosin-ll would be fully saturated, seven 
of the monoclonal antibodies did not inhibit the actomyosin- 
II ATPase activity; neither did Alice, a monoclonal antibody 
to chicken pectoralis (skeletal) muscle myosin that does not 
bind to myosin-II. Thus, antibodies inhibit the actin activated 
ATPase  activity  only  if they  bind  to  specific  sites  on  the 
myosin-II molecule. 
Inhibition of actomyosin-II ATPase activity is not due to 
proteolysis of myosin-II by components of the various anti- 
body preparations (Fig.  1). We electrophoresed preparations 
of myosin-II on polyacrylamide gels in SDS to evaluate the 
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TABLE  I 
Inhibition of Actomyosin-lf ATPase Activity by Molar Excess of 
Monoclonal  Antibody 
Ratio of an-  Free myosin 
Molar  tibody con-  concen-  Fraction 
ratio  centration  tration  of con- 
antibody:  to apparent  (calcu-  trol 
Antibody  myosin  Ko*  lated)*  activity 
M2.X 
1  106.  365  0.27%  .14 
2  36.  39  2.67  .78 
3  86.  1479  0.07  .07 
4  41.  176  0.57  .11 
5  120.  51600  0.002  ,50 
6  39.  560  0.18  .11 
7  35.  --  --  .08 
8  8.  s  86  1.33  .52 
9  21.  56  1.83  .22 
10  130.  1398  0.07  .05 
11  24.  206  0.52  .87 
12  68.  77  1.31  .64 
13  14.  151  0.71  .14 
15  70.  1003  0.10  .96 
16  19.  s  t36  0.77  .41 
17  80.  491  0.21  .76 
18  53.  87  1.13  1.04 
19  63.  226  0.45  .25 
20  80.  344  0.30  .16 
21  m  _  _  _ 
22  72.  238  0.42  .90 
26  62.  533  0.04  .07 
27  39.  335  0.30  .14 
Alice(control)  45.  --  --  .93 
Apparent Ka for each antibody was determined with a solid-phase  binding 
assay. The method and the tabulated values appear in reference 12. 
* Free myosin concentration is expressed  as a percent of the total myosin in 
the assay and  was  calculated  assuming  that a single  antibody  molecule 
binds  to a single myosin  molecule in simple equilibrium  with an apparent 
dissociation  constant as described in  reference 12. The  actual  reaction is 
likely to be far more complex, but our data (see Figs. 2 and 5) suggests that 
in  all  cases where inhibition  was observed,  binding  of a single  antibody 
molecule to myosin  is sufficient to completely inhibit actomyosin ATPase 
activity or gel contraction. Thus we consider our assumption  valid  to a first 
approximation. 
s Antibodies M2.8 and -16 are IgMs, and therefore have five times as many 
binding  sites  per  molecule as the other Igs. The  molar ratio in  terms of 
binding site equivalents  is therefore 37.4 and 96.1, respectively. 
'Antibody 21 was not grown in sufficient quantities to allow testing. 
polypeptide composition of the  myosin-II before and  after 
incubation with the antibodies under conditions used for the 
actomyosin-II ATPase assays. Incubation with the antibodies 
did not alter the electrophoretic mobility of either the myosin- 
II heavy or light chains. 
Concentration  Dependence  of Antibody 
Inhibition of A TPase Activity 
Antibodies inhibit  the  actin activated ATPase activity of 
myosin-II in a concentration-dependent fashion (Fig. 2). Plots 
of actomyosin-II ATPase activity versus antibody concentra- 
tion  show the extent of inhibition and the stoichiometry of 
antibody to myosin required to cause maximum inhibition 
for each antibody studied. 
Certain  antibodies  are potent  inhibitors  (e.g.,  M2.1,  -10, 
and -27) that block actomyosin-II  ATPase activity completely. 
Many  of the  antibodies  are  only  partial  inhibitors  of the 
actomyosin-II ATPase as manifest by residual, but depressed, 
ATPase activities even  in  the  presence of a  vast excess of FIGURE  1  SDS  PAGE of myosin-II  alone or myosin-II  incubated 
with antibodies under the same conditions as in the actomyosin 
ATPase assay. The  polypeptide composition of the  myosin-II  is 
unaffected by incubation with antibody. (Lanes M) Myosin-II alone. 
(Numbered  lanes) Myosin-II  incubated  with  specific  antibody 
(M2.x).  (Lane A)  Myosin-II  incubated  with  Alice,  a  monoclonal 
antibody against chicken pectoralis myosin subfragment-1 that does 
not bind to myosin-II.  Migration of molecular weight standards are 
shown to the right of each gel. Numbers at lower right indicate the 
molecular weights (x10-3).  M2HC,  myosin-II  heavy chain.  IgHC, 
immunoglobulin heavy chain.  IgLC, immunoglobulin light chain. 
M2LC, myosin-II  light chain. 
inhibitor (e.g.,  M2.3,  -6, and -9).  Certain antibodies do not 
inhibit at all (e.g., Alice and M2.11, see also Table I). 
In  most  cases,  maximum  inhibition  occurs  with  molar 
ratios of antibody to myosin-II of close to  1:1. This concen- 
tration dependence holds for both partial and complete inhib- 
itors of actomyosin-II ATPase activity (compare M2.1,  -10, 
and -27 with M2.4 and -6) and suggests that inhibition is due 
to a  specific interaction between the purified antibody and 
myosin. The most significant exceptions are antibodies M2.3 
and -19, which  require  1.5  and threefold molar excesses of 
antibody, respectively, for maximal inhibition. 
The extent to which each specific antibody inhibitor affects 
the actomyosin-II ATPase rate varied somewhat. Duplicate 
preparations assayed at the same time were nearly identical 
and routinely varied by <2%. However, we analysed the effect 
of molar excesses of antibodies  M2.1  and  -3  on  the  acto- 
myosin-II ATPase  activity  l0  or  more  times  each,  using 
purified myosin from five different preparations. Inhibition 
ranged from 84-98%  (mean =  87%,  S.D.  7%,  n  =  10) for 
M2.1  and from 70-90% (mean =  79%, S.D. =  9%, n =  ll) 
for M2.3. Antibody M2.4, a member of the largest family of 
related  antibodies  inhibited  actomyosin-II ATPase  activity 
82-98% (mean =  90%, S.D. =  8%, n =  3). Other antibodies 
including those that sometimes completely inhibited the ac- 
tomyosin-II  ATPase  activity  displayed  similar  variability 
(M2.10, range of inhibition 91-100%, mean =  94%, S.D. = 
4%, n  =  4).  The reason for this variability remains unclear 
but seems due to the subtle differences in the preparations of 
Acanthamoeba actin used for these assays. 
We investigated the mechanism of antibody inhibition of 
actomyosin-II ATPase by traditional enzyme kinetic methods 
(such as reciprocal rate versus reciprocal actin concentration 
plots as a function of  antibody concentrations), but our studies 
were inconclusive because of the  nonlinearity of the  plots, 
even  in  the  absence  of antibody  (data  not  shown).  This 
confirms the  observations  of Collins  and  Korn  (3).  Such 
nonlinearity of the double reciprocal plots is probably because 
both actin and myosin-II are present as filaments rather than 
freely diffusing monomers under the conditions used to max- 
imize  actin  activation  of the  Mg++-ATPase  of myosin-II, 
namely low salt and high Mg  ÷÷ (l 7, 28; and Kiehart, unpub- 
lished observations). 
Fab Fragments Also Inhibit the Actomyosin- 
II ATPase 
Fab fragments of antibodies M2. l  and -3 inhibit the acto- 
myosin-II ATPase  rate.  We  made  Fab  fragments  of two 
1.2 
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FIGURE 2  Inhibition of actomyosin-II ATPase  activity is antibody 
concentration dependent. The antibodies are identified on each 
graph (M2.x). Myosin-II concentration was 0.43/zM and Acantham- 
oeba actin concentration was 11.8 p.M. 
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terminants  on  the  myosin-II heavy  chain  by  bifunctional 
antibodies was required for inhibition of actomyosin-II AT- 
Pase  activity.  Fab  M2.1  was  an  effective inhibitor  of the 
actomyosin-II ATPase as shown in Fig. 3. Maximal inhibition 
by antibody  M2.1  and  by  Fab M2.1  occurred  at  approxi- 
mately 1:1  ratios of antigen combining sites to myosin pep- 
tides. At least twice as many moles of Fab as antibody were 
required because the whole antibody has two antigen-binding 
sites,  the Fab fragments, only one. Also, the Fab fragments 
may have a slightly lower affinity for myosin-II and may have 
been damaged during proteolytic cleavage of the antibody for 
Fab preparation. 
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FIGURE  3  Fab  fragments  of  M2.1  inhibit  actomyosin-II  ATPase 
activity. Myosin-II concentration was 0.43  #M and Acanthamoeba 
actin concentration was 11.8 #M. Curves are labeled according to 
which antibody or Fab fragment was used. Alice is a monoclonal 
antibody against chicken pectoralis myosin subfragment-1  that does 
not react with myosin-II. 
Antibodies Inhibit Contraction of Gelled Extracts 
of Acanthamoeba Cytoplasm 
The monoclonal antibodies also inhibit the contraction of 
gelled cytoplasmic extracts, an in vitro model system for cell 
motility. When high speed supernatants of sucrose extracts of 
Acanthamoeba  cytoplasm are allowed to warm they form a 
gel.  With  time the  gelled  extract becomes translucent  and 
contracts, syneresing a  clear fluid phase (Fig.  4).  We mixed 
high speed supernatant of Acanthamoeba  with each antibody 
to test their effects on gelation and contraction. 
In separate experiments, we used a solid-phase radio-bind- 
ing assay to estimate that the concentration of myosin-II in 
the extracts was ~0.24 vM, a value comparable to 0.6 vM in 
intact cells (data not shown). This value is close to the 0.7- 
uM value estimated for myosin-II  concentration in intact cells 
by densitometry of SDS gels (31).  We describe the effects of 
the antibodies in terms of their stoichiometry to their target 
antigen, myosin-II. 
None of the monoclonal antibodies inhibit the gelation of 
Acanthamoeba  extracts. Within  10 min of warming to room 
temperature, each sample of  extract containing a molar excess 
of monoclonal antibody formed a gel as verified by the falling 
ball assay. Controls, which included antibody buffer alone or 
high  concentrations  of Alice,  an  antibody  against  chicken 
pectoralis muscle myosin subfragment-1 that does not bind 
to myosin-II, also had no effect. 
14 of 19 monoclonal antibodies tested inhibit gel contrac- 
tion (Table II). 11 of the  14 inhibitory antibodies also inhibit 
actomyosin-II ATPase  activity.  Antibodies  M2.2,  -15,  and 
-17 did not affect actomyosin-II ATPase activity but inhibit 
gel contraction. Alice (see above) and several specific mono- 
FIGURE  4  Contraction of gelled extracts of Acanthamoeba  cytoplasm in the presence of various concentrations of Fab fragments 
of antibody M2.1. A schematic of a capillary is shown at the bottom and is described in Materials and Methods. The extent of 
contraction is measured as the distance that the translucent gel pulls away from the seal at the left and is equivalent to the length 
of the column of syneresed  fluid. The antibody concentrations (left}  are the ratio of antibody to myosin-II (~0.24 #M} in  the 
extracts.  Duplicate samples for each concentration demonstrate the reproducibility of the assay. With  increasing antibody, the 
extent of contraction is diminished. 
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antibodies allowed contraction to an intermediate extent. 
Antibodies inhibit gel  contraction  in  a  concentration-de- 
pendent  fashion  (Fig.  5).  We  varied  the  concentration  of 
antibody  we  added  to  cell  extracts  and  found  that  most 
antibodies inhibited gel contraction maximally when the stoi- 
chiometry of specific antibody to extract myosin-II was some- 
what less than  l: I. Some antibodies inhibit contraction corn- 
TABLE  II 
Inhibition of Gel Contraction by Molar Excess of Monoclonal 
Antibody 
Antibody 
Molar ra-  Ratio of anti- 
tio anti-  body con-  Free myosin  Fraction of 
body/  centration to  concentration  control 
myosin  apparent KD*  (calculated)*  activity 
M2.X 
1  17.0  328  0.32  0 
2  7.0  43  2.66  0 
3  15.0  1,440  0.07  0 
4  7.0  530  0.68  0.05 
5  22.0  53,000  0.002  0.49 
6  7.0  567  0.20  0.04 
7  --  -- 
8  --  -- 
9  4.0  63  2.05  0.17 
10  23.0  1375  0.08  0 
11  2.0  100  1.86  1.02 
12  12.0  76  1.41  0.17 
13  3.0  175  0.86  0.11 
15  13.0  1,033  0.10  0 
16  **  -- 
17  14.0  485  0.22  0.05 
18  10.0  92  1.19  1.23 
19  11.0  217  0.51  0.54 
20  14.0  340  0.32  0 
21  *  -- 
22  13.0  239  0.45  1.13 
26  11.0  2,600  0.04  0 
27  7.0  340  0.34  0 
Alice  8.0  --  1.03 
* See legend for Table I. 
* Antibodies  M2.7 and -21 were not grown in sufficient  quantities  to allow 
testing. 
t Antibodies  M2.8 and -16 are IgMs and were not tested. 
pletely. Other specific antibodies, like control antibodies that 
do not bind to myosin-II, have no effect. Still other antibodies 
inhibit contraction only partially, even when there is a large 
molar excess of antibody over myosin. 
Contraction,  like  actomyosin-II ATPase  activity,  varied 
inversely with antibody concentration. We directly compared 
the antibody concentration dependence of inhibition of ac- 
tomyosin-II ATPase activity to inhibition of gel contraction 
in  two ways.  Fig.  6  shows  inhibition  of both processes by 
antibody M2.10.  The fraction of control actomyosin-II AT- 
Pase activity and control gel contraction are each plotted as a 
function  of the  ratio of antibody M2.10  to  myosin-II. Re- 
markably, inhibition of both processes can be described by a 
single curve. For most of the other antibodies, the concentra- 
tion dependence of inhibition of actomyosin-II ATPase activ- 
ity and gel contraction fall on similar but  not precisely the 
same curves (compare Figs. 3 and 5). 
Comparison of inhibition of actomyosin-II ATPase activity 
and of gel contraction for all the antibodies appears in Fig. 7. 
We plot the  molar ratio of antibody to myosin required to 
inhibit gel contraction to 50% of maximum versus the molar 
ratio of antibody to myosin required to inhibit actomyosin-II 
ATPase activity to 50%  of maximum. Most antibodies fall 
into one of two groups. Antibodies that are potent inhibitors 
of both processes fall near the origin, at the lower left. Those 
that inhibit neither process appear diagonally opposed, in the 
upper right. Antibodies M2.2, - 15, and - 17 are notable excep- 
tions because they block gel contraction without influencing 
actomyosin-II ATPase  activity.  Conversely, M2.19  inhibits 
the actomyosin-II ATPase but does not appear to affect gel 
contraction. 
DISCUSSION 
Monoclonal Antibodies Are Specific and Potent 
Inhibitors of Mechanochemical Function 
Monoclonal  antibodies  can  be  both  specific and  potent 
inhibitors of myosin-II function in vitro. They are specific in 
that antibodies that bind to at least  11  distinct  sites on the 
myosin-II molecule block function, while antibodies that bind 
to at  least four other sites have no influence on  myosin-II 
filament formation (13,  14), actomyosin-II ATPase activity 
or the contraction of gelled extracts of amoeba cytoplasm. In 
FIGURE  5  Inhibition  of gel  con- 
traction is antibody concentration 
dependent.  Gel  contraction  ex- 
pressed as the fraction of gel con- 
traction  in  the  absence  of  anti- 
body. Concentration of antibody 
is given as the ratio of antibody to 
myosin-II  in  the  extract  (~0.24 
pM).  Antibody  numbers  (M2.x) 
are identified on each graph. 
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FIGURE 6  Dependence of actomyosin-ll ATPase activity (O) and 
cytoplasmic  extract contraction (e) on the concentration of anti- 
body M2.10. Alice, a monoclonal antibody against chicken pector- 
alis myosin  subfragment-1  that does not bind to myosin-II  affects 
neither actomyosin-II ATPase activity ([3), or gel  contraction (11). 
Conditions for  the  actomyosin-II ATPase assay are  given  in  the 
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FIGURE 7  Graphical comparison of antibody inhibition of gel con- 
traction and ATPase  activity. A plot of the concentration of antibody 
(expressed as the ratio of antibody to myosin-II)  required to cause 
50% inhibition of gel contraction versus the concentration of the 
same antibody required to cause 50% inhibition of actomyosin-II 
ATPase activity.  Antibodies which are effective inhibitors of both 
processes fall close to the origin, at the lower left. Antibodies which 
inhibit neither process will fall opposite, at the upper right. Condi- 
tions for the actomyosin-II ATPase assays  appear in Fig. 2. 
all cases, the ability of the antibodies to inhibit the function 
of myosin was tested at antibody concentrations at least 39- 
fold greater than the apparent dissociation constant for anti- 
body binding to myosin-II (Tables I and II). The apparent KD 
was measured with a solid-phase binding assay. The methods 
and  tabulated  values  for  the  various  antibodies  appear  in 
reference 12. Assuming that inhibition requires one antibody 
molecule bound to myosin (Figs.  2 and 5) we calculate that 
even  in  the  worst  case  (highest  apparent  KD  with  lowest 
concentration of antibody), >97% of the myosin-II was com- 
plexed with antibody. On  average the concentration of free 
myosin in  these  assays was <1%  of total  myosin-II in  the 
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assay.  Thus  free  myosin  cannot  account  for  all  the  acto- 
myosin-II ATPase activity observed in these assays.  We con- 
clude that binding of antibody to certain sites on the myosin- 
II  molecule  inhibits  actomyosin-II ATPase  activity  or  gel 
contraction,  while binding to certain other sites has no ob- 
servable effect on these functions. 
Antibodies to three other sites,  M2.2, - 15, and - 17 have a 
unique  effect:  they  appear  to  uncouple  contraction  from 
actomyosin-II ATPase activity. We have not localized their 
binding sites precisely, but M2.2 must bind somewhere near 
M2.4 because it stains similar constellations of peptides on a 
number of the  peptide  maps and  M2.17  must bind to  the 
myosin-II heads, because its antigenic determinant is on the 
70,000-mol-wt tryptic fragment of the myosin-II heavy chain 
(13,  14). 
The antibodies are potent in that saturation of certain single 
antigenic sites on each myosin-II heavy chain can completely 
inhibit polymerization, actomyosin-II ATPase activity and/ 
or gel contraction. These antibodies abolished the ability of 
myosin to function as a mechanochemical energy transducing 
protein.  In  other  cases,  inhibition  was  extensive,  but  not 
complete: activity decreased with antibody concentration to 
a certain extent, then plateaued. Again, in most cases,  inhi- 
bition was nearly maximal when a  single  antigenic site was 
saturated with antibody. A relatively constant, residual acto- 
myosin-II ATPase activity or contraction remained, even in 
the  presence  of vast  molar  excesses  of antibody.  This  is 
classical  partial  inhibition  (34).  The  antibody  hinders,  but 
does not abolish myosin function, presumably by binding to 
a site that decreases, but does not completely inhibit, substrate 
turnover. 
Complete inhibition of  gel contraction by certain antibodies 
against myosin-II identifies myosin-II as the major mechan- 
ochemical  energy-transducing  protein  in  this  model  of 
amoeba motility and shows that myosin-I alone cannot con- 
tract the gelled extracts. It was already known that a partially 
purified myosin-II, but  not myosin-I, caused contraction of 
Acanthamoeba actin gels reconstituted from purified proteins 
(23).  However, this failure of myosin-I could have been due 
to  the  absence of accessory proteins  required  for myosin-I 
function. Our experiments with a crude cytoplasmic extract, 
that  is  likely to  contain  all  of the  accessory proteins,  and 
purified antibodies that bind to myosin-II but not myosin-I, 
provides even stronger evidence that myosin-I is not sufficient 
for  gel  contraction.  It  is  our  hope  that  microinjection  of 
antibodies into living amoebae will answer the more impor- 
tant question of the in vivo functions of myosin-I and -II. 
Since none of the antibodies to myosin-II inhibit gelation 
of the cytoplasmic extracts, it is unlikely that myosin-II is a 
major actin filament cross-linker in these extracts. Even those 
antibodies  that  block  myosin-II polymerization (M2.3  and 
-9;  see  reference  13)  had  no  effect  on  time  required  for 
gelation. Although  it is very likely that myosin-II filaments 
bridge two or more actin  filaments, at  least transiently,  to 
generate the tension required for contraction, gelation prob- 
ably occurs when stable cross-links between actin filaments 
are formed by the other actin-binding proteins found in the 
amoeba (22,  23, 27). 
Mechanisms of Myosin-II  Inactivation 
by Antibodies 
The  mechanism  by  which  each  antibody  affects  the 
mechanochemical function of myosin-II depends on exactly T^BLE I11 
Summary of Antibody Binding Sites and the Effect of Antibodies 
on Myosin-II  Function 
Inhibited  Function" 
No  Filament 
effect  formation 
Acto- 
myosin-II 
ATPase  Gel con- 




11,  18  + 
17 
Proximal end of the tail 
2 
4, 6,  7, 26, 27 
22  + 
Tail 
3,9 
12  + 
Unknown 
5,  13,  19, 20 
15 
+  + 
+ 
+  + 
+  +  + 
Filament formation data is from reference 13. Antibody M2.21  has not yet 
been available in sufficient quantity to test its effect on myosin-II function. 
Antibodies M2.8 and M2.16 are IgMs and are not soluble under the assay 
conditions required to test actomyosin-ATPase activity, gel contraction or 
filament formation. We assayed their effect on actomyosin-II ATPase activ- 
ity; neither was an inhibitor. 
* "+" indicates that the function was inhibited. 
where  the  antibody  binds  to  the  myosin-II molecule.  The 
location  of antibody-binding  sites  (13)  and  their  effect on 
myosin function are summarized in Table IlL Antibodies that 
bind to the tip of  the myosin-II  tail cannot inhibit actomyosin- 
II ATPase activity by the same mechanism as those that bind 
to the myosin-II heads. For this reason, we will consider the 
action  of each antibody in  terms of its binding  site in  the 
following sections. At the outset,  however, we consider the 
evidence that none of the antibodies interfere with function 
by inhibiting ATP binding or nonspecific precipitation of the 
myosin-II. 
None of  the antibodies specifically inhibits the rate of either 
the Ca  ++- or K+-EDTA-ATPases of myosin alone. Since the 
specific activities of these enzyme functions are comparable 
to the  specific activity of the actin activated ATPase at the 
concentration of actin we typically use, we conclude that any 
influence on ATP binding or on conformational changes in 
the ATP-binding site that are required  for catalysis are not 
rate limiting and are unlikely to be responsible for the inhi- 
bition of the actomyosin-II ATPase activity. 
Antibodies do  not  appear to  inhibit  myosin function  by 
cross-linking or  precipitating  myosin-II molecules,  because 
Fab fragments of two antibodies that bind to opposite ends 
of the myosin-II molecule (M2.1  and -3) both inhibit acto- 
myosin-II ATPase activity and gel contraction  to the same 
extent as the intact antibodies. It will be important to test Fab 
fragments of the other antibodies when we study their mech- 
anism of inhibition in more detail. 
The  other  general  mechanisms by which  the  antibodies 
may influence myosin function fall into two broad categories: 
local effects or long range effects.  Local effects might include 
direct  steric  interference  with  actin  binding  or  with  some 
mobility or flexibility of the myosin-II molecule required for 
cross-bridge cycling. We tried to evaluate antibody effects on 
actin binding by myosin-II using a pelleting assay. Unfortu- 
nately,  part  of the  complexes  of myosin-II and  antibody 
pelleted in the ultracentrifuge even in the absence of actin, so 
Fab fragments of the antibodies will be required to determine 
whether or not the antibodies hinder actin binding. We con- 
sider inhibition of actin binding a likely mechanism by which 
at least some of the antibodies block myosin-II function. 
Mechanisms of Inhibition by Anti- 
Head A n tibodies 
Two  antibodies M2.1  and  -10,  bind  close  to  or  on  the 
myosin-II heads as shown by electron microscopy (13),  and 
both are potent inhibitors of actomyosin-II ATPase activity 
and gel contraction. Electron microscopy, competitive bind- 
ing studies, and staining of one-dimensional peptide maps all 
indicate that M2.1 binds to a different part of the heads than 
M2.10.  Because antibody M2.10 competes, albeit poorly, for 
binding with the core family that includes M2.4, -6, -7, and 
-26, it is likely that M2.10 binds at the base of the head, close 
to  or even at  the junction  with  the  tail  (12,  13). Another 
antibody,  M2.27  may bind  nearby, because it,  like M2.10, 
inhibits ATPase activity more strongly than other members 
of the family that includes M2.4, -6, -7, and -26. Antibodies 
that bind to the head are likely to inhibit the mechanochem- 
ical  function  of myosin-II by  either  interfering  with  actin 
binding or by altering the structure of the head. We cannot 
distinguish  between these mechanisms at this time.  It is of 
course not  at all  surprising that  antibodies directed  against 
the heads exert a profound effect on mechanochemical func- 
tion by myosin. 
In contrast, two other antibodies that bind to the myosin- 
II heads have no effect on the actin activated ATPase activity 
of myosin-II. Antibodies M2.17 and -18 bind to the 70,000- 
mol-wt tryptic fragment of myosin-II and therefore unambig- 
uously bind to the myosin-II heads (12).  This peptide can be 
photoaffinity labeled with ATP in the catalytic site (24),  but 
the  specific site where  M2.18  binds may not  participate in 
mechanochemical energy transduction. Antibody M2.17 ap- 
pears to  uncouple gel  contraction  from ATPase activity. It 
has little influence on ATPase activity, yet inhibits gel con- 
traction (Tables I and II). The lack of inhibition by these two 
antibodies also suggests  that  rotational and/or translational 
diffusion of the  myosin-II heads is not  rate limiting in  the 
actomyosin-lI ATPase reaction.  If it were, the greater than 
twofold increase in the mass of the heads caused by the bound 
antibodies would surely influence the rate. The mechanism 
by which  M2.17  blocks gel  contraction will  require  further 
investigation. 
Mechanisms of Inhibition by Antibodies That 
Bind to the Myosin-II Tail Adjacent to the Heads 
Three classes of antibodies bind to the myosin-II tail near 
to where it joins the myosin-II heads. Some antibodies block 
both actomyosin-II ATPase activity and gel-contraction, one 
blocks  only gel  contraction  and  one  inhibits  neither  acto- 
myosin-II ATPase  activity  or  gel  contraction.  These  three 
classes of antibodies that bind the tail near the myosin heads 
must recognize different domains that participate in myosin 
function in profoundly different ways. 
Remarkably,  most  of the  antibodies  that  bind  near  the 
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-21, -26, and -27) are potent and specific inhibitors of acto-
myosin-II ATPase activity and gel contraction. By analogy
with other myosin molecules, we expect that the actin-binding
sites of myosin-II are on a part of the heads distal to their
junction with the tail. Consequently, it seems unlikely that
antibodies such as M2.4, that bind to the myosin-II tail -20
nm from the myosin-II heads, interfere directly with actin
binding. The simplest interpretation is that these antibodies
inhibit ATPase activity and gel contraction through their
influence on the structure of myosin in the local region to
which they bind. They may lock this region of the molecule
into a conformation that prohibits the structural changes
necessary for catalytic and contractile function. This implies
that in the region to which these antibodies bind, these
processes are tightly coupled to conformational changes in
the structure of myosin.
Antibody M2.2 is very interesting because like M2.15 and
-17 it appears to uncouple contraction from actomyosin-II
ATPase activity. We have not localized the binding site pre-
cisely, but it must bind somewhere near M2.4, because it
stains similar constellations of peptides on a number of the
peptide maps. We speculate that the conformational changes
on this part of the tail that are required for catalysis differ
subtly from those required for contraction. Perhaps the
changes required for mechanochemical coupling are much
more extensive than those required for catalysis.
Antibody M2.22 binds to another site on the myosin-II tail
near the heads but has no effect on ATPase activity or
contraction. The localization of this binding site relative to
those that influence function should provide important in-
sights into the mechanism ofenergy transduction by myosin-
II.
The tail region of myosin-II adjacent to the heads may be
the counterpart of one or both of the presumed hinge regions
that link the heads of muscle myosin to subfragment-2 and
subfragment-2 to light meromyosin. A special feature of the
structure ofthe myosin-II molecule is that it may have either
no or only a very short subfragment-2 region (18, 28). The
whole muscle myosin tail is probably an alpha-helical coil
(20, 21), but the regions that flank the 50 nm long, stable
subfragment-2 segment contain protease-sensitive sites and
one displays a quasi-independent thermal instability near
physiological temperatures (40). These regions are referred to
as hinges because they are flexible enough to allow the myosin
heads to rotate fairly freely (38) and the whole subfragment-
2/head region to swing out from the backbone of the thick
filament (8, 18, 25). Harrington and his co-workers (7, 40)
have even suggested that the subfragment-2/light meromyosin
hinge region undergoes conformational changes that results
in mechanochemical energy transduction by actomyosin.
These experiments pose some serious questions about
whether the myosin headsare fully active energy transducers
independent oftheir normal association with the tail. On one
hand, muscle myosin subfragment-1 retains full actomyosin
ATPase activity (37) and can generate movements by inter-
acting with actin filaments in in vitro model systems (42; also
recently reviewed in references 5, 35). On the other hand,
inhibition of both actomyosin-II ATPase activity and gel
contraction by antibodies that bind to the proximal end of
the myosin-II tail provides strong evidence that this part of
the myosin-II tail actively participates in mechanochemical
energy transduction. This discrepancy may be explained by
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fundamental differences in the mechanism of force produc-
tion by skeletal muscle and cytoplasmic myosins. Models for
the mechanism of force production by cytoplasmic myosins
(and perhaps by other myosins) have to account for a struc-
turally important site in the proximal end of the myosin-II
tail is intimately involved in the ability ofmyosin to hydrolyze
ATP and perform work.
Our observations on the importance of the region of the
tail adjacent to the heads are compatible with the helix-coil
transition model for force productionby myosin (7), that calls
on the hinge region to participate in mechanochemical energy
transduction. In fact, experiments to test whether the antibod-
ies stabilize the region of the tail adjacent to the heads and
prevent the thermal melt and helix-random coil transition
could provide direct evidence for this model. The results with
these antibodies are also compatible with other models for
force production, provided that the antibodies inhibit confor-
mational changes in the tail and thereby allosterically influ-
ence the structural changes in the myosin head that occur
during cross-bridge cycling.
There is additional evidence that the part of the myosin
molecule near the junction of the heads and tail is important
in the regulation of myosin. The myosin regulatory light
chains have been localized to a site on the myosin head distal
to the actin-binding site near where the heads meet the tail
(41). Phosphorylation of the myosin regulatory light chains
of vertebrate cytoplasmic myosins and smooth muscle myo-
sins influences filament formation, actomyosin ATPase activ-
ity and even the gross conformation of the myosin (1, 4, 33,
39). Likewise, Ca" binding by some invertebrate muscle
myosins requires regulatory light chains and regulates the
actomyosin ATPase activity (reviewed recently in reference
6).
Mechanism of Inhibition by Anti-TailAntibodies
There is a good correlation between the ability ofan anti-
body to inhibit filament formation and to inhibit actomyosin-
II ATPase activity. Two antibodies, M2.3 and -9, bind to the
tip of the myosin-II tail, inhibit filament formation, acto-
myosin-II ATPase activity and gel contraction. A third anti-
body, M2.12, also binds to the tip of the myosin-II tail, but
does not inhibit either filament formation or ATPase activity.
This evidence suggests that antibodies that bind to the tip of
the myosin-II tail probably inhibit ATPase activity and gel
contraction through the inhibition of myosin-II filament for-
mation. In experiments described elsewhere, we supply further
support for this mechanism by demonstrating a good corre-
lation between the time course of disassembly of preformed
myosin-II filaments by antibody M2.3 and the concomitant
loss of actomyosin-II ATPase activity (14). The correlation
holds under two widely different ionic conditions where fila-
ments differ profoundly in morphology and stability.
The experiments reported here confirm that neither ofthe
two antibodies (M2.3 and -9) that appear to inhibit acto-
myosin-II ATPase activity by preventing myosin-II filament
assembly reduce the ATPase to zero (14). The residual acto-
myosin-II ATPase activity is probably attributable to depo-
lymerized myosin-II. This means that the depolymerized
myosin-II has a specific activity of -50-100 nmol - min' .
mg-' in 0.5 mg/ml actin and that assembly into filaments
stimulates the activity 5-10-fold. This could be by one oftwo
possible mechanisms. The significance of these findings andtheir relevance to other studies on the influence of polymeri- 
zation  of myosin  on  its  actin  activated  ATPase  activity  is 
discussed elsewhere (14). 
Myosin-II filaments are probably required for gel contrac- 
tion.  While  residual  actomyosin-II  ATPase  activity  in  the 
presence of excess antibody  M2.3  is -20%  of control values, 
inhibition of gel contraction by M2.3 is more nearly complete. 
This suggests that either the  actin  activated  ATPase  charac- 
teristic of monomeric myosin-II produces forces insufficient 
for gel contraction  or more likely, that bipolar filaments are 
required for mechanical reasons to generate the force required 
for gel contraction. 
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